218 related articles for article (PubMed ID: 20836676)
1. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T; Robak E
Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
[TBL] [Abstract][Full Text] [Related]
3. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
4. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
Gururajan M; Dasu T; Shahidain S; Jennings CD; Robertson DA; Rangnekar VM; Bondada S
J Immunol; 2007 Jan; 178(1):111-21. PubMed ID: 17182546
[TBL] [Abstract][Full Text] [Related]
5. Getting Syk: spleen tyrosine kinase as a therapeutic target.
Geahlen RL
Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
[TBL] [Abstract][Full Text] [Related]
6. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Kenkre VP; Kahl BS
Curr Hematol Malig Rep; 2012 Sep; 7(3):216-20. PubMed ID: 22688757
[TBL] [Abstract][Full Text] [Related]
7. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
10. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.
Uckun FM; Ek RO; Jan ST; Chen CL; Qazi S
Br J Haematol; 2010 May; 149(4):508-17. PubMed ID: 20151979
[TBL] [Abstract][Full Text] [Related]
11. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
12. The Syk kinase as a therapeutic target in leukemia and lymphoma.
Efremov DG; Laurenti L
Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
[TBL] [Abstract][Full Text] [Related]
13. [Syk inhibitors].
Kimura Y; Chihara K; Takeuchi K; Sada K
Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
[TBL] [Abstract][Full Text] [Related]
14. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
16. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
17. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
19. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
20. Syk expression patterns differ among B-cell lymphomas.
Ponzoni M; Uccella S; Mian M; Rinaldi A; Facchetti F; Pruneri G; Gaidano G; Capella C; Zucca E; Doglioni C; Bertoni F
Leuk Res; 2010 Sep; 34(9):e243-5. PubMed ID: 20378171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
